Elanco Announces Changes to Board of Directors; Signs Research Agreement to Explore Novel Therapies for Chronic Kidney Disease and Life Extension in Pets
Elanco Animal Health (NYSE: ELAN) announced significant changes to its Board of Directors, reducing the board size to 11 directors by the 2025 Annual Meeting. Three directors - JP Bilbrey, Kathy Turner, and Craig Wallace - will not seek re-election, while William F. Doyle has resigned immediately.
Paul Herendeen will succeed Bilbrey as Chair of the Board's Finance, Strategy and Oversight Committee. The company recently added Dr. Stacey Ma to refresh Board composition.
Additionally, Elanco signed a research agreement with WEDterinary , a newly formed research entity co-founded by Doyle. The partnership will focus on:
- Developing targeted gene therapy treatments for Chronic Kidney Disease (CKD) in cats
- Exploring innovative approaches to increase healthy lifespan in pets
- Utilizing new technologies like gene therapy and AI
The research agreement will be funded within Elanco's existing R&D operating expenses.
Elanco Animal Health (NYSE: ELAN) ha annunciato cambiamenti significativi nel suo Consiglio di Amministrazione, riducendo la dimensione del consiglio a 11 membri entro l'Assemblea Annuale del 2025. Tre membri - JP Bilbrey, Kathy Turner e Craig Wallace - non si ricandideranno, mentre William F. Doyle si è dimesso immediatamente.
Paul Herendeen succederà a Bilbrey come Presidente del Comitato Finanza, Strategia e Vigilanza del Consiglio. L'azienda ha recentemente aggiunto la Dott.ssa Stacey Ma per rinnovare la composizione del Consiglio.
Inoltre, Elanco ha firmato un accordo di ricerca con WEDterinary, un'entità di ricerca di recente formazione co-fondata da Doyle. La partnership si concentrerà su:
- Sviluppare trattamenti mirati di terapia genica per la Malattia Renale Cronica (CKD) nei gatti
- Esplorare approcci innovativi per aumentare la durata della vita sana negli animali domestici
- Utilizzare nuove tecnologie come la terapia genica e l'IA
L'accordo di ricerca sarà finanziato all'interno delle spese operative di R&D esistenti di Elanco.
Elanco Animal Health (NYSE: ELAN) anunció cambios significativos en su Junta Directiva, reduciendo el tamaño de la junta a 11 directores para la Junta Anual de 2025. Tres directores - JP Bilbrey, Kathy Turner y Craig Wallace - no buscarán la reelección, mientras que William F. Doyle ha renunciado de inmediato.
Paul Herendeen sucederá a Bilbrey como Presidente del Comité de Finanzas, Estrategia y Supervisión de la Junta. La empresa ha añadido recientemente a la Dra. Stacey Ma para refrescar la composición de la Junta.
Además, Elanco firmó un acuerdo de investigación con WEDterinary, una entidad de investigación recién formada cofundada por Doyle. La asociación se centrará en:
- Desarrollar tratamientos de terapia génica dirigidos para la Enfermedad Renal Crónica (ERC) en gatos
- Explorar enfoques innovadores para aumentar la vida saludable de las mascotas
- Utilizar nuevas tecnologías como la terapia génica y la IA
El acuerdo de investigación será financiado dentro de los gastos operativos de I+D existentes de Elanco.
엘란코 애니멀 헬스 (NYSE: ELAN)는 이사회의 규모를 2025년 정기총회까지 11명으로 줄이는 중대한 변화를 발표했습니다. JP 빌브리, 캐시 터너, 크레이그 월리스의 세 이사가 재선에 나서지 않을 것이며, 윌리엄 F. 도일은 즉시 사임했습니다.
폴 헤렌딘이 빌브리의 후임으로 이사회 재무, 전략 및 감독 위원회의 의장이 됩니다. 회사는 최근 이사회 구성을 새롭게 하기 위해 스테이시 마 박사를 추가했습니다.
또한 엘란코는 도일이 공동 설립한 새로 형성된 연구 기관인 WEDterinary와 연구 협약을 체결했습니다. 이 파트너십은 다음에 중점을 둘 것입니다:
- 고양이의 만성 신장 질환(CKD)을 위한 표적 유전자 치료법 개발
- 반려동물의 건강한 수명 연장을 위한 혁신적인 접근 방식 탐색
- 유전자 치료 및 AI와 같은 새로운 기술 활용
연구 협약은 엘란코의 기존 R&D 운영 비용 내에서 자금을 지원받을 것입니다.
Elanco Animal Health (NYSE: ELAN) a annoncé des changements significatifs dans son Conseil d'Administration, réduisant la taille du conseil à 11 membres d'ici l'Assemblée Générale de 2025. Trois membres - JP Bilbrey, Kathy Turner et Craig Wallace - ne se représenteront pas, tandis que William F. Doyle a démissionné immédiatement.
Paul Herendeen succédera à Bilbrey en tant que Président du Comité des Finances, de la Stratégie et de la Surveillance du Conseil. L'entreprise a récemment ajouté le Dr Stacey Ma pour rafraîchir la composition du Conseil.
De plus, Elanco a signé un accord de recherche avec WEDterinary, une entité de recherche récemment formée cofondée par Doyle. Le partenariat se concentrera sur :
- Développer des traitements ciblés de thérapie génique pour la Maladie Rénale Chronique (MRC) chez les chats
- Explorer des approches innovantes pour augmenter la durée de vie saine des animaux de compagnie
- Utiliser de nouvelles technologies comme la thérapie génique et l'IA
L'accord de recherche sera financé dans le cadre des dépenses opérationnelles de R&D existantes d'Elanco.
Elanco Animal Health (NYSE: ELAN) hat bedeutende Änderungen in seinem Vorstand angekündigt, indem die Größe des Vorstands bis zur Jahreshauptversammlung 2025 auf 11 Direktoren reduziert wird. Drei Direktoren - JP Bilbrey, Kathy Turner und Craig Wallace - werden sich nicht zur Wiederwahl stellen, während William F. Doyle sofort zurückgetreten ist.
Paul Herendeen wird Bilbrey als Vorsitzender des Finanzausschusses, Strategie und Aufsicht des Vorstands nachfolgen. Das Unternehmen hat kürzlich Dr. Stacey Ma hinzugefügt, um die Zusammensetzung des Vorstands zu erneuern.
Darüber hinaus hat Elanco eine Forschungsvereinbarung mit WEDterinary unterzeichnet, einer neu gegründeten Forschungseinrichtung, die von Doyle mitbegründet wurde. Die Partnerschaft wird sich auf Folgendes konzentrieren:
- Entwicklung gezielter Gentherapien für chronische Nierenerkrankungen (CKD) bei Katzen
- Erforschung innovativer Ansätze zur Verlängerung der gesunden Lebensdauer von Haustieren
- Nutzung neuer Technologien wie Gentherapie und KI
Die Forschungsvereinbarung wird aus den bestehenden Betriebskosten der F&E von Elanco finanziert.
- Strategic research partnership with WEDterinary to develop innovative pet treatments
- Board restructuring maintains needed expertise mix for effective oversight
- Expansion into emerging technologies (gene therapy, AI) for pet healthcare
- Research agreement funded within existing R&D budget, requiring no additional expenses
- Loss of four experienced board members, including Finance Committee Chair
- Potential execution risks in entering new technological areas (gene therapy, AI)
- John P. (JP) Bilbrey, Kathy Turner and Craig Wallace have each informed the Board they will not stand for re-election at the conclusion of their terms at the 2025 Annual Meeting of Shareholders.
- William F. (Bill) Doyle has resigned from the Board, effective immediately, in connection with entering into a research agreement with Elanco through his affiliated entity.
"On behalf of the Board, I want to thank JP, Bill, Kathy and Craig for their service to Elanco," said Lawrence Kurzius, Chairman of the Elanco Board of Directors. "JP's experience from the boardroom to the ranch has been invaluable to the Elanco Board and we appreciate his years of service since Elanco became a fully independent public company, including his leadership of the Board's Finance, Strategy and Oversight Committee. Similarly, Bill has brought significant animal health, health care and innovation expertise since joining the Board in 2020. We also extend our appreciation to Kathy and Craig for their contributions as Elanco moved its innovation pipeline from the regulatory phase into commercialization this past year."
The Corporate Governance Committee has recommended Paul Herendeen succeed Mr. Bilbrey as Chair of the Board's Finance, Strategy and Oversight Committee. Mr. Herendeen joined the Board in 2020 as an investor representative, bringing deep expertise in finance, the animal health and pharma industries. Elanco recently refreshed Board composition with the addition of Dr. Stacey Ma. The Board continues to represent the needed mix of expertise and backgrounds to provide effective oversight as Elanco executes its plans to accelerate growth through its diverse portfolio of innovation.
"I'm grateful to my fellow Board members and Elanco leadership for the robust engagement these last years as we navigated Elanco's standup, integration and the creation of a global, independent animal health leader that I'm confident is well positioned for long-term sustained growth," Bilbrey said. "With the late-stage pipeline delivered, the strategy streamlined and commercialization well underway, now is the right time for me to retire."
Research Agreement to Treat Chronic Kidney Disease (CKD) and Explore Approaches for Life Extension in Pets
As part of Elanco's efforts to help pets live longer, healthier, more active lives, the Company has also signed a research agreement with WEDterinary LLC, a newly formed research engine co-founded by Mr. Doyle and a team of scientists, to pursue transformational approaches to health care for pets. In connection with this relationship, Mr. Doyle will continue to advise Elanco on related animal health innovation.
The initial phase will focus on several high potential programs using targeted gene therapy to treat CKD in cats and explore emerging spaces to increase healthy lifespan for pets. Shifting pet ownership to younger generations and the increased time spent with pets during COVID have increased both pet owners' expectation of care and willingness to spend to protect pet health.
"Elanco is excited to partner with WEDterinary to pioneer new spaces in animal health using new technologies like gene therapy and AI," said Dr. Ellen de Brabander, Executive Vice President of R&D and Regulatory Affairs at Elanco Animal Health. "We believe Bill's experience with Novocure and his history of bringing transformational, non-traditional innovation approaches to the market can unlock emerging innovation opportunities. Ultimately, the partnership increases our research capacity to refill our innovation pipeline and drive a consistent flow of high impact innovation to improve the lives of pets and their families."
"I am eager to partner with the Elanco research and development team I know well to bring our years of cutting-edge human pharma research to bear in animal health," Doyle said. "I believe combining Elanco's expertise with the latest platforms and capabilities under development for human health can create opportunities to revolutionize pet care."
The agreement will be funded within Elanco's research and development operating expenses.
ABOUT ELANCO
Elanco Animal Health Incorporated (NYSE: ELAN) is a global leader in animal health dedicated to innovating and delivering products and services to prevent and treat disease in farm animals and pets, creating value for farmers, pet owners, veterinarians, stakeholders and society as a whole. With 70 years of animal health heritage, we are committed to breaking boundaries and going beyond to help our customers improve the health of animals in their care, while also making a meaningful impact on our local and global communities. At Elanco, we are driven by our vision of Food and Companionship Enriching Life and our Elanco Healthy Purpose™ sustainability pillars – all to advance the health of animals, people, the planet and our enterprise. Learn more at www.elanco.com.
ABOUT WEDterinary LLC
Founded by William Doyle and a team of scientists, WEDterinary LLC is focused on developing novel therapies for the global veterinary market leveraging deep knowledge and expertise in human health.
Investor Contact: Tiffany Kanaga (765) 740-0314 tiffany.kanaga@elancoah.com
Media Contact: Colleen Dekker (317) 989-7011 colleen.dekker@elancoah.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/elanco-announces-changes-to-board-of-directors-signs-research-agreement-to-explore-novel-therapies-for-chronic-kidney-disease-and-life-extension-in-pets-302403531.html
SOURCE Elanco Animal Health
FAQ
What changes are happening to Elanco's (ELAN) Board of Directors in 2025?
What is the focus of Elanco's (ELAN) new research agreement with WEDterinary?
Who will be the new Chair of Elanco's (ELAN) Finance, Strategy and Oversight Committee?
How will Elanco (ELAN) fund the WEDterinary research agreement?
